The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1561
Baloxavir Marboxil (Xofluza) for Treatment of Influenza
The full article is available to subscribers Subscriber Login   

The FDA has approved baloxavir marboxil (Xofluza – Shionogi/Genentech), the first polymerase acidic (PA) endonuclease inhibitor, for single-dose, oral treatment of acute uncomplicated influenza in patients ≥12 years old. Baloxavir is the first drug with a new mechanism of action to be approved for treatment of influenza in almost 20 years.

STANDARD TREATMENT — Neuraminidase inhibitors, which are active against both influenza A and B viruses, have been the drugs of choice for treatment and prophylaxis of influenza for many years. They are most effective when started within 48 hours after symptom onset.1 Oral oseltamivir (Tamiflu, and generics) and inhaled zanamivir (Relenza) are FDA-approved for treatment and prophylaxis of influenza. IV peramivir (Rapivab) is FDA-approved only for treatment of influenza. Neuraminidase ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Baloxavir Marboxil (Xofluza) for Treatment of Influenza
Article code: 1561a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian